stockportfolio.pro
Stocks / GRAL vs GRDN
GRAL vs GRDN
GRAIL, Inc. and Guardian Pharmacy Services, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| GRAIL, Inc. (GRAL) | Guardian Pharmacy Services, Inc. (GRDN) | |
|---|---|---|
| Market cap | $2.6B | $2.7B |
| Revenue (latest FY) | $147.17M | $1.45B |
| Net income (latest FY) | $-408.35M | $49.22M |
| Revenue growth (5y CAGR) | 38.4% | 16.8% |
| Net margin | -277.5% | 3.4% |
| Return on equity | -15.8% | 23.9% |
| P/E ratio | — | 50.1 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 3 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GRAL — free Open GRDN — freeFrequently asked questions
Which is bigger, GRAL or GRDN?
Guardian Pharmacy Services, Inc. is larger by market capitalization — $2.7B versus $2.6B.
Which grows faster, GRAL or GRDN?
Over the last five fiscal years, GRAIL, Inc. grew revenue faster — 38.4%/yr versus 16.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.